The impact of the National Shingles Vaccination Program on the epidemiology of herpes zoster among adults ≥ 60 years in Victoria, Australia
DOI:
https://doi.org/10.33321/cdi.2023.47.56Keywords:
Herpes zoster, herpes zoster vaccine, vaccine-preventable diseases, epidemiologyAbstract
IntroductionIn November 2016, Australia recommended herpes zoster (HZ) vaccination for adults aged ≥ 60 years and implemented a National Shingles Vaccination Program (NSVP) offering free HZ vaccination to adults aged 70–79 years. This study investigated trends in HZ epidemiology among Victorian adults aged ≥ 60 years and the impact of the NSVP in this population.
MethodsWe conducted epidemiological analyses of routinely collected HZ surveillance data for Victorian adults aged ≥ 60 years who were notified as having a HZ illness or vaccination between 2012 and 2021. Annual incidence rates are presented for vaccinations, case notifications, emergency department presentations, hospitalisations and deaths by five-year age groups. Age-specific incidence rate ratios are calculated comparing the period prior to (1 January 2012 to 31 October 2016) and following (1 November 2016 to 31 December 2021) NSVP implementation.
ResultsHZ vaccination rates were highest among those eligible to receive free vaccination (70–79 years), but appear to have plateaued across all age groups and remained below full coverage. Incidence rate ratios showed a statistically significant increase (p < 0.01) in HZ notifications across all age-groups. Emergency presentations and hospitalisations showed a statistically significant decline (p < 0.05) among the 70–79 year old age groups; however, these rates remained consistent or increased among other age groups for whom vaccination is recommended. Mortality rates declined, particularly among those aged 85+ years.
DiscussionHZ continues to cause significant disease among the older adult population in Victoria. The findings of this study suggest the NSVP has led to some changes in the epidemiology of HZ among the 70–79 years old age group in Victoria; however, there is less evidence that it has influenced other age groups for whom vaccination is recommended. An evaluation of the NSVP and epidemiology of HZ at a national level is required to identify strategies to improve vaccination coverage among the target populations.
Downloads
References
MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10(4):e0125025. doi: https://doi.org/10.1371/journal.pone.0125025.
National Centre for Immunisation Research and Surveillance (NCIRS). Zoster vaccines for Australian adults. Sydney: NCIRS; July 2021. Available from: https://www.ncirs.org.au/sites/default/files/2021-07/Zoster%20vaccine%20for%20Australian%20adults%20fact%20sheet_19%20July%202021_Final.pdf.
Australian Government Department of Health and Aged Care, Australian Immunisation Handbook. Zoster (herpes zoster). [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 7 December 2022. [Accessed on May 7 2023.] Available from: https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/zoster-herpes-zoster.
Jayasinghe S, Sheridan S, Macartney K. Herpes zoster vaccination in Australia: what’s available and who benefits? Aust Prescr. 2020;43(1):2–6. doi: https://doi.org/10.18773/austprescr.2020.001.
Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–60. doi: https://doi.org/10.1093/infdis/jiy095.
Australian Government Department of Health and Aged Care. Shingles (herpes zoster) vaccine. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 28 September 2022. Available from: https://www.health.gov.au/topics/immunisation/vaccines/shingles-herpes-zoster-immunisation-service.
Australian Government Department of Health and Aged Care. National Immunisation Program: Shingles vaccination catch-up program extended. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 15 October 2021. Available from: https://www.health.gov.au/news/national-immunisation-program-shingles-vaccination-catch-up-program-extended.
Services Australia. Budget 2023-24. National Immunisation Program. Canberra: Services Australia; 9 May 2023. [Accessed on 5 June 2023.] Available from: https://www.servicesaustralia.gov.au/sites/default/files/2023-05/budget-2023-24-may-health-and-disability-9.pdf.
Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program. Vaccine. 2020;38(20):3646–52. doi: https://doi.org/10.1016/j.vaccine.2020.03.036.
Litt J, Booy R, Bourke D, Dwyer DE, Leeb A, McCloud P et al. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Hum Vaccin Immunother. 2020;16(12):3081–9. doi: https://doi.org/10.1080/21645515.2020.1754702.
Rashid H, Dey A, Manocha R, Tashani M, Macartney K, Beard F. Australia’s national zoster vaccination program: knowledge, attitudes and behaviour of general practitioners. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.59.
Lin J, Dobbins T, Wood JG, Bernardo C, Stocks NP, Liu B. Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. Vaccine. 2021;39(10):1493–8. doi: https://doi.org/10.1016/j.vaccine.2021.01.067.
Lin J, Dobbins T, Wood JG, Bernardo C, Stocks NP, Liu B. Impact of a national immunisation program on herpes zoster incidence in Australia. J Infect. 2022;84(4):537–41. doi: https://doi.org/10.1016/j.jinf.2022.01.011.
Lin J, Dobbins T, Wood JG, Hall JJ, Liu B. Impact of a structured older persons health assessment on herpes zoster vaccine uptake in Australian primary care. Prev Med. 2022;155:106946. doi: https://doi.org/10.1016/j.ypmed.2021.106946.
NCIRS. Evaluation of the National Shingles Vaccination Program Process and early impact evaluation. Final Report. Sydney: NCIRS; 1 March 2019.Available from: https://ncirs.org.au/sites/default/files/2019-04/Shingles%20Program%20Evaluation%20Report_1%20March%202019_Final%20for%20web.pdf.
Phakey S, Rogers SL, Hall AJ, Lim LL. Reduction in herpes zoster antiviral use since the introduction of the live-attenuated zoster vaccine on Australia’s National Immunisation Program: a population-based study from 1994 to 2019. Infect Dis Ther. 2023;12(2):711–26. doi: https://doi.org/10.1007/s40121-022-00749-y.
Communicable Diseases Network Australia (CDNA). Varicella-zoster (shingles). Australian national notifiable diseases case definition. Canberra: Australian Government Department of Health and Aged Care, CDNA; 1 January 2018. [Accessed on 13 October 2022.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/varicella-zoster-shingles-surveillance-case-definition.pdf.
CDNA. Varicella zoster (unspecified). Australian national notifiable diseases case definition. Canberra: Australian Government Department of Health and Aged Care, CDNA; 1 January 2018. [Accessed on 13 October 2022.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/varicella-zoster-unspecified-surveillance-case-definition.pdf.
Victoria State Government Department of Health. Notifiable infectious diseases, conditions and micro-organisms. [Webpage.] Melbourne: Victoria State Government Department of Health; 27 July 2023. [Accessed on 27 July 2023.] Available from: https://www.health.vic.gov.au/infectious-diseases/notifiable-infectious-diseases-conditions-and-micro-organisms.
StataCorp LLC. STATA statistical software: release 17. [Software.] College Station: StataCorp LLC; 2021. Available from: https://www.stata.com/company/.
Australian Bureau of Statistics. National, state and territory population. Reference period: March 2022. [Webpage.] Canberra: Australian Bureau of Statistics; 21 September 2022. [Accessed on 13 October 2022.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2022.
NCIRS. Herpes zoster. Zoster vaccine for Australian adults: information for immunisation providers. Sydney: NCIRS; August 2017. [Accessed on 19 September 2022.] Available from: https://www.ncirs.org.au/sites/default/files/2018-12/zoster-vaccine-fact-sheet.pdf.
Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y et al. Increased risk of herpes zoster in adults ≥ 50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022;9(5):ofac118. doi: https://doi.org/10.1093/ofid/ofac118.
Kadambari S, Abo YN, Phuong LK, Osowicki J, Bryant PA. Decrease in infection-related hospital admissions during COVID-19: why are parents avoiding the doctor? Pediatr Infect Dis J. 2020;39(11):e385–6. doi: https://doi.org/10.1097/INF.0000000000002870.
de Albuquerque Veloso Machado M, Roberts B, Wong BLH, van Kessel R, Mossialos E. The relationship between the COVID-19 pandemic and vaccine hesitancy: a scoping review of literature until August 2021. Front Public Health. 2021;9:747787. doi: https://doi.org/10.3389/fpubh.2021.747787.
Hull BP, Hendry AJ, Dey A, Bryant K, Radkowski C, Pellissier S et al. The impact of the COVID-19 pandemic on routine vaccinations in Victoria. Med J Aust. 2021;215(2):83–4. doi: https://doi.org/10.5694/mja2.51145.
Victoria State Government. Health Services (Health Service Establishments) Regulations 2013. [Legislation.] Melbourne: Victoria State Government; 1 July 2018. [Accessed on 17 October 2022.] Available from: https://www.health.vic.gov.au/sites/default/files/migrated/files/collections/policies-and-guidelines/h/health-service-establishments-regulations-2013.pdf.
Hull B, Hendry AJ, Dey A, Macartney K, McIntyre P, Beard F. Exploratory analysis of the first 2 years of adult vaccination data recorded on AIR. Sydney: NCIRS; November 2019. Available from: https://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
